Careless talk costs lives: Fibroblast growth factor receptor signalling and the consequences of pathway malfunction

Trends in Cell Biology

Volumn 25, Issue 4, 2015, Pages 221-233

  Carter, Edward P ^a   Fearon, Abbie E ^a   Grose, Richard P ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer; Cell signalling; Fibroblast growth factor; Fibroblast growth factor receptor

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; PHOSPHOTRANSFERASE INHIBITOR; FIBROBLAST GROWTH FACTOR;

ALLOSTERISM; AUTOCRINE EFFECT; DRUG TARGETING; GENE AMPLIFICATION; GENE FUSION; GENE MUTATION; HUMAN; LIVER; LUNG; NONHUMAN; ORTHOSTERIC RECEPTOR BINDING; PATHOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SKIN; TISSUE REGENERATION; TISSUE REPAIR; HOMEOSTASIS; METABOLISM; MUTATION; NEOPLASM; PHOSPHORYLATION;

FIBROBLAST GROWTH FACTORS; GENE FUSION; HOMEOSTASIS; HUMANS; MUTATION; NEOPLASMS; PHOSPHORYLATION; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84925456768     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2014.11.003     Document Type: Review

References (136)

1. Belov, A.A. and Mohammadi, M. (2013) Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb. Perspect. Biol. 5 Published online June 1, 2013. doi:10.1101/cshperspect.a015958.
2. Holzmann K., et al. Alternative splicing of fibroblast growth factor receptor IgIII loops in cancer. J. Nucleic Acids 2011, 2012:950508.
3. Sleeman M., et al. Identification of a new fibroblast growth factor receptor, FGFR5. Gene 2001, 271:171-182.
4. Catela C., et al. Multiple congenital malformations of Wolf-Hirschhorn syndrome are recapitulated in Fgfrl1 null mice. Dis. Model Mech. 2009, 2:283-294.
5. Bluteau G., et al. Targeted disruption of the intracellular domain of receptor FgfrL1 in mice. PLoS ONE 2014, 9:e105210.
6. Silva P.N., et al. Fibroblast growth factor receptor like-1 (FGFRL1) interacts with SHP-1 phosphatase at insulin secretory granules and induces beta-cell ERK1/2 protein activation. J. Biol. Chem. 2013, 288:17859-17870.
7. Goetz R., Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat. Rev. Mol. Cell Biol. 2013, 14:166-180.
8. Goetz R., et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol. 2007, 27:3417-3428.
9. Goetz R., et al. Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J. Biol. Chem. 2012, 287:29134-29146.
10. Goetz R., et al. Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol. Cell. Biol. 2012, 32:1944-1954.
11. Lew E.D., et al. The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci. Signal. 2009, 2:ra6.
12. Mohammadi M., et al. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol. Cell. Biol. 1991, 11:5068-5078.
13. Kouhara H., et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 1997, 89:693-702.
14. Hart K.C., et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000, 19:3309-3320.
15. Ong S.H., et al. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6074-6079.
16. Wong A., et al. FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:6684-6689.
17. Smith T.G., et al. Negative feedback predominates over cross-regulation to control ERK MAPK activity in response to FGF signalling in embryos. FEBS Lett. 2006, 580:4242-4245.
18. Ding W., et al. Functional analysis of the human Sprouty2 gene promoter. Gene 2003, 322:175-185.
19. Kovalenko D., et al. Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation. J. Biol. Chem. 2003, 278:14087-14091.
20. Zakrzewska M., et al. ERK-mediated phosphorylation of fibroblast growth factor receptor 1 on Ser777 inhibits signaling. Sci. Signal. 2013, 6:ra11.
21. Lin C.C., et al. Inhibition of basal FGF receptor signaling by dimeric Grb2. Cell 2012, 149:1514-1524.
22. Ahmed Z., et al. Grb2 controls phosphorylation of FGFR2 by inhibiting receptor kinase and Shp2 phosphatase activity. J. Cell Biol. 2013, 200:493-504.
23. Timsah Z., et al. Competition between Grb2 and Plcgamma1 for FGFR2 regulates basal phospholipase activity and invasion. Nat. Struct. Mol. Biol. 2014, 21:180-188.
24. Fearon A.E., Grose R.P. Grb-ing receptor activation by the tail. Nat. Struct. Mol. Biol. 2014, 21:113-114.
25. Francavilla C., et al. Functional proteomics defines the molecular switch underlying FGF receptor trafficking and cellular outputs. Mol. Cell 2013, 51:707-722.
26. Makarenkova H.P., et al. Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis. Sci. Signal. 2009, 2:ra55.
27. Coleman S.J., et al. The ins and outs of fibroblast growth factor receptor signalling. Clin. Sci. (Lond.) 2014, 127:217-231.
28. Mills I.G. Nuclear translocation and functions of growth factor receptors. Semin. Cell Dev. Biol. 2011, 23:165-171.
29. Chioni A.M., Grose R. FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior. J. Cell Biol. 2012, 197:801-817.
30. Coleman S.J., et al. Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. EMBO Mol. Med. 2014, 6:467-481.
31. Lee Y.W., et al. A novel nuclear FGF Receptor-1 partnership with retinoid and Nur receptors during developmental gene programming of embryonic stem cells. J. Cell. Biochem. 2012, 113:2920-2936.
32. Baron O., et al. Cooperation of nuclear fibroblast growth factor receptor 1 and Nurr1 offers new interactive mechanism in postmitotic development of mesencephalic dopaminergic neurons. J. Biol. Chem. 2012, 287:19827-19840.
33. Lee Y.W., et al. NGF-induced cell differentiation and gene activation is mediated by integrative nuclear FGFR1 signaling (INFS). PLoS ONE 2013, 8:e68931.
34. Zakrzewska M., et al. Translocation of exogenous FGF1 into cytosol and nucleus is a periodic event independent of receptor kinase activity. Exp. Cell Res. 2011, 317:1005-1015.
35. Zhen Y., et al. Nuclear import of exogenous FGF1 requires the ER-protein LRRC59 and the importins Kpnalpha1 and Kpnbeta1. Traffic 2012, 13:650-664.
36. Smallwood P.M., et al. Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:9850-9857.
37. Liu C.J., et al. Modulation of the cardiac sodium channel Nav1.5 by fibroblast growth factor homologous factor 1B. J. Biol. Chem. 2003, 278:1029-1036.
38. Yan H., et al. FGF14 regulates presynaptic Ca2+ channels and synaptic transmission. Cell Rep. 2013, 4:66-75.
39. Hennessey J.A., et al. Fibroblast growth factor homologous factors modulate cardiac calcium channels. Circ. Res. 2013, 113:381-388.
40. Pownall M.E., Isaacs H.V. FGF Signalling in Vertebrate Development 2010, Morgan & Claypool Life Science, San Rafael (CA).
41. Hatch N.E. FGF signaling in craniofacial biological control and pathological craniofacial development. Crit. Rev. Eukaryot. Gene Expr. 2010, 20:295-311.
42. Yu K., et al. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:14536-14541.
43. Park W.J., et al. Analysis of phenotypic features and FGFR2 mutations in Apert syndrome. Am. J. Hum. Genet. 1995, 57:321-328.
44. Wang Y., et al. Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse. Development 2005, 132:3537-3548.
45. Chen P., et al. A Ser252Trp mutation in fibroblast growth factor receptor 2 (FGFR2) mimicking human Apert syndrome reveals an essential role for FGF signaling in the regulation of endochondral bone formation. PLoS ONE 2014, 9:e87311.
46. Yokota M., et al. Therapeutic effect of nanogel-based delivery of soluble FGFR2 with S252W mutation on craniosynostosis. PLoS ONE 2014, 9:e101693.
47. Dode C., et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat. Genet. 2003, 33:463-465.
48. Thurman R.D., et al. Molecular basis for the Kallmann syndrome-linked fibroblast growth factor receptor mutation. Biochem. Biophys. Res. Commun. 2012, 425:673-678.
49. McCabe M.J., et al. Novel FGF8 mutations associated with recessive holoprosencephaly, craniofacial defects, and hypothalamo-pituitary dysfunction. J. Clin. Endocrinol. Metab. 2011, 96:E1709-E1718.
50. Arauz R.F., et al. A hypomorphic allele in the FGF8 gene contributes to holoprosencephaly and is allelic to gonadotropin-releasing hormone deficiency in humans. Mol. Syndromol. 2010, 1:59-66.
51. McGrath J.A., et al. Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum. Mol. Genet. 2001, 10:221-229.
52. Ferone G., et al. Mutant p63 causes defective expansion of ectodermal progenitor cells and impaired FGF signalling in AEC syndrome. EMBO Mol. Med. 2012, 4:192-205.
53. Hennessey J.A., et al. FGF12 is a candidate Brugada syndrome locus. Heart Rhythm 2013, 10:1886-1894.
54. Yang J., et al. Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis. J. Cell Biol. 2010, 188:935-952.
55. Jameson J., et al. A role for skin gammadelta T cells in wound repair. Science 2002, 296:747-749.
56. Gay D., et al. Fgf9 from dermal gammadelta T cells induces hair follicle neogenesis after wounding. Nat. Med. 2013, 19:916-923.
57. Werner S., et al. Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:6896-6900.
58. Werner S., et al. The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science 1994, 266:819-822.
59. Meyer M., et al. FGF receptors 1 and 2 are key regulators of keratinocyte migration in vitro and in wounded skin. J. Cell Sci. 2012, 125:5690-5701.
60. Oladipupo S.S., et al. Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:13379-13384.
61. Taub R. Liver regeneration: from myth to mechanism. Nat. Rev. Mol. Cell Biol. 2004, 5:836-847.
62. Bohm F., et al. Regulation of liver regeneration by growth factors and cytokines. EMBO Mol. Med. 2010, 2:294-305.
63. Steiling H., et al. Fibroblast growth factor receptor signalling is crucial for liver homeostasis and regeneration. Oncogene 2003, 22:4380-4388.
64. Bohm F., et al. FGF receptors 1 and 2 control chemically induced injury and compound detoxification in regenerating livers of mice. Gastroenterology 2010, 139:1385-1396.
65. Yu C., et al. Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice. Am. J. Pathol. 2002, 161:2003-2010.
66. Lin B.C., et al. Liver-specific activities of FGF19 require Klotho beta. J. Biol. Chem. 2007, 282:27277-27284.
67. Takase H.M., et al. FGF7 is a functional niche signal required for stimulation of adult liver progenitor cells that support liver regeneration. Genes Dev. 2013, 27:169-181.
68. Uriarte I., et al. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut 2013, 62:899-910.
69. Hines E.A., Sun X. Tissue crosstalk in lung development. J. Cell. Biochem. 2014, 115:1469-1477.
70. Volckaert T., et al. Parabronchial smooth muscle constitutes an airway epithelial stem cell niche in the mouse lung after injury. J. Clin. Invest. 2011, 121:4409-4419.
71. Coffey E., et al. Expression of fibroblast growth factor 9 in normal human lung and idiopathic pulmonary fibrosis. J. Histochem. Cytochem. 2013, 61:671-679.
72. Yu Z.H., et al. Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice. Biol. Pharm. Bull. 2012, 35:731-736.
73. Aguilar S., et al. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS ONE 2009, 4:e8013.
74. Guzy R.D., et al. FGF2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin. Am. J. Respir. Cell Mol. Biol. 2014, Published online July 2, 2014.
75. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.
76. Kim S., et al. FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells. PLoS ONE 2013, 8:e51671.
77. Wan X., et al. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci. Transl. Med. 2014, 6:252ra122.
78. Chang J., et al. Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis. PLoS ONE 2014, 9:e105524.
79. Soria J.C., et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann. Oncol. 2014, 25:2244-2251. 2014.
80. Andre F., et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin. Cancer Res. 2013, 19:3693-3702.
81. Weiss J., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2010, 2:62ra93.
82. Reintjes N., et al. Activating somatic FGFR2 mutations in breast cancer. PLoS ONE 2013, 8:e60264.
83. Tchaicha J.H., et al. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Res. 2014, 74:4676-4684.
84. Hunter D.J., et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 2007, 39:870-874.
85. Easton D.F., et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093.
86. Huijts P.E., et al. Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10. Breast Cancer Res. 2011, 13:R72.
87. Liu X., et al. Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis. Genet. Mol. Res. 2014, 13:1109-1120.
88. Sung J.Y., et al. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy. Urol. Oncol. 2013, 32:49. e23-31.
89. Juanpere N., et al. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Hum. Pathol. 2012, 43:1573-1582.
90. Foth M., et al. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice. J. Pathol. 2014, 233:148-158.
91. Kalff A., Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J. 2012, 2:e89.
92. Shern J.F., et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014, 4:216-231.
93. Taylor J.G., et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest. 2009, 119:3395-3407.
94. Parker B.C., et al. Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J. Pathol. 2014, 232:4-15.
95. Williams S.V., et al. Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 2012, 22:795-803.
96. Wang R., et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin. Cancer Res. 2014, 20:4107-4114.
97. Singh D., et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337:1231-1235.
98. Parker B.C., et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J. Clin. Invest. 2013, 123:855-865.
99. Arai Y., et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2013, 59:1427-1434.
100. Wu Y.M., et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013, 3:636-647.
101. Yan G., et al. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol. Cell. Biol. 1993, 13:4513-4522.
102. Shirakihara T., et al. TGF-beta regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J. 2011, 30:783-795.
103. Ishiwata T., et al. Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am. J. Pathol. 2012, 180:1928-1941.
104. Kawase R., et al. Expression of fibroblast growth factor receptor 2 IIIc in human uterine cervical intraepithelial neoplasia and cervical cancer. Int. J. Oncol. 2010, 36:331-340.
105. Peng W.X., et al. Altered expression of fibroblast growth factor receptor 2 isoform IIIc: relevance to endometrioid adenocarcinoma carcinogenesis and histological differentiation. Int. J. Clin. Exp. Pathol. 2014, 7:1069-1076.
106. Marshall M.E., et al. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin. Cancer Res. 2011, 17:5016-5025.
107. Hertzler-Schaefer K., et al. Pten loss induces autocrine FGF signaling to promote skin tumorigenesis. Cell Rep. 2014, 6:818-826.
108. Feng S., et al. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res. 2013, 73:2551-2562.
109. Ware K.E., et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2013, 2:e39.
110. Terai H., et al. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol. Cancer Res. 2013, 11:759-767.
111. O'Hare T., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
112. Gozgit J.M., et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 2012, 11:690-699.
113. The Medical Letter Online In brief: ponatinib (Inclusig) returns. Med. Lett. Drugs Ther. 2014, 56:8.
114. Gavine P.R., et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012, 72:2045-2056.
115. Guagnano V., et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 2011, 54:7066-7083.
116. Zhao G., et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol. Cancer Ther. 2011, 10:2200-2210.
117. Konecny G.E., et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol. Cancer Ther. 2013, 12:632-642.
118. Xie L., et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 2013, 19:2572-2583.
119. Zhang J., et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin. Cancer Res. 2012, 18:6658-6667.
120. Sequist L.V., et al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. [abstract]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research 2014.
121. Dienstmann R., et al. First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors [abstract]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research 2014.
122. Sun H.D., et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E964-E976.
123. Qing J., et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Invest. 2009, 119:1216-1229.
124. Bai A., et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 2010, 70:7630-7639.
125. Carpenter T.O., et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J. Clin. Invest. 2014, 124:1587-1597.
126. Harding T.C., et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci. Transl. Med. 2013, 5:ra39.
127. Garcia S., et al. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Sci. Transl. Med. 2013, 5:203ra124.
128. Yamashita A., et al. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature 2014, 513:507-511.
129. Herbert C., et al. Molecular mechanism of SSR 128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell 2013, 23:489-501.
130. Bono F., et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 2013, 23:477-488.
131. Hilberg F., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008, 68:4774-4782.
132. Matsui J., et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int. J. Cancer 2008, 122:664-671.
133. Laird A.D., et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000, 60:4152-4160.
134. Fletcher G.C., et al. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol. Cancer Ther. 2010, 10:126-137.
135. Bello E., et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011, 71:1396-1405.
136. Trudel S., et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005, 105:2941-2948.